Niowave has broken ground on a $75 million Actinium-225 (Ac-225) production facility in Lansing, MI, its second dedicated production site in the city.
The facility will feature multiple proprietary superconducting linear accelerators along with processing and quality systems to support scalable Ac-225 production. Construction is being led by the Christman Company in collaboration with Colliers Engineering & Design. Niowave said construction is expected to be completed by 2028.
Ac-225 is an alpha-emitting isotope used in targeted cancer therapies designed to destroy cancer cells while minimizing damage to healthy tissue. Niowave has signed two major Ac-225 supply agreements in the past four months with AstraZeneca and Novartis. The new facility is expected to create approximately 70 jobs, according to the company.
